1. Pink Sheet
  3. >>Clinical Trials
  4. >>Real-World Evidence

RWE Program Offers Sponsors Chance At Novel Uses, But In Exchange For Disclosing Proposals

 
• By Derrick Gingery

The disclosure requirement to participate includes an option for the US FDA to include the ideas on new regulatory uses for real-world evidence in a guidance or speak about them at public forums in order to ‘promote innovation.’

Electronic health record
The Advancing Real-World Evidence Program will accept proposals twice per year. • Source: Shutterstock

US Food and Drug Administration officials are ready consider novel ideas for using real-world evidence to support labeling changes or meet postmarket requirements, but in return program participants must allow some public discussion of them.

Agency officials on 19 October announced the launch of the Advancing Real-World Evidence (RWE) Program, which is among the commitments...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Real-World Evidence

More from Clinical Trials

EU’s Life Sciences Strategy Faces Race Against Time, Says Clinical Trials Community

 
• By Vibha Sharma

The report gave examples of missed opportunities for innovation and patient access, as well as regulatory and operational problems that undermine the conduct of timely clinical trials in Europe.

Sponsors Asked, EMA Delivered: One Handbook To Navigate CTIS

 
• By Vibha Sharma

The European Medicines Agency has revised the sponsor handbook for the Clinical Trials Information System, bringing together guidance that was previously scattered across multiple platforms and documents to help sponsors navigate the trial process more efficiently.

Sarepta Refuses To Stop Elevidys Shipments After Third Death Linked To Gene Therapy Vector

 
• By Mandy Jackson

Sarepta knew about the death in a Phase I trial of SRP-9004 for LGMD when it recently revealed a restructuring plan, but did not disclose the event. The now-discontinued gene therapy candidate uses the same AAV vector as Elevidys, which has been linked to two DMD patient deaths.